Alexza Pharmaceuticals first-one fourth net loss boosts to $13 www.medicine-rx.com.

Alexza Pharmaceuticals first-one fourth net loss boosts to $13.4 million Alexza Pharmaceuticals, Inc. today reported monetary results for the initial quarter ended March 31, 2010 and provided an ongoing business update www.medicine-rx.com .4 million and $6.9 million, respectively.0 million. Alexza Business Updates The following key events occurred since the beginning of the first quarter of 2010: Alexza established its first collaboration for AZ-004 with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, for the united states and Canada.Alexza received notification from the FDA that its AZ-004 NDA was accepted for filing and the PDUFA objective date is October 11, 2010.IN-MAY, Alexza executed a $15.0 million working capital loan agreement with Hercules Technology Development Capital.